Orano Med
Sharon Gorgolini is a CMC Research Associate II at Orano Med, with experience in in vitro studies, experimental protocols optimization, and peptide testing. Previously, Sharon worked as a Teacher at Elementary Schools of San Marino and as a Substitute Teacher at High School, Middle School, and Elementary Schools of San Marino. Sharon also has experience as a Research Intern at Karolinska Institutet and IRCCS Istituto Nazionale dei Tumori Foundation, where Sharon conducted cancer research projects for their experimental degree theses. Sharon holds a Master's degree in Pharmaceutical Biotechnology and a Bachelor's degree in Biotechnology.
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.